OmniAb, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OABI Nasdaq 2836 www.omniab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OmniAb, Inc.

OmniAb, Inc. (NASDAQ:OABI) has caught the attention of institutional investors who hold a sizeable 36% stake - Jan 6th, 2026 5:28 am
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies - Dec 15th, 2025 2:05 pm
Here's Why We're Not Too Worried About OmniAb's (NASDAQ:OABI) Cash Burn Situation - Dec 10th, 2025 4:43 am
OmniAb to Hold OmniUltra Virtual Investor Event on December 15 - Dec 4th, 2025 2:05 pm
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors - Nov 17th, 2025 3:23 pm
John Higgins Bought 3.5% More Shares In OmniAb - Nov 13th, 2025 3:51 am
Analysts Have Been Trimming Their OmniAb, Inc. (NASDAQ:OABI) Price Target After Its Latest Report - Nov 8th, 2025 6:27 am
OmniAb (OABI): Rapid 30.4% Revenue Growth Forecast Raises Questions for Loss-Weary Investors - Nov 5th, 2025 9:41 pm
OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue Decline - Nov 4th, 2025 10:06 pm
OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates - Nov 4th, 2025 4:35 pm
OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 4th, 2025 2:05 pm
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Oct 30th, 2025 8:00 am
OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? - Oct 28th, 2025 8:00 am
Insider Stock Buying Reaches US$1.48m On OmniAb - Oct 28th, 2025 7:17 am
Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? - Oct 16th, 2025 6:55 am
OmniAb to Participate in Three Investor Conferences in November - Oct 16th, 2025 6:00 am
OmniAb to Report Third Quarter 2025 Financial Results on November 4 - Oct 14th, 2025 6:00 am
OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 6:00 am
OmniAb Announces $30 Million Private Placement - Aug 25th, 2025 5:00 am
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments - Aug 20th, 2025 6:00 am